Skip to main content

Advertisement

Log in

Aktueller Einsatz von PSA

How to use PSA in 2009

  • Themenschwerpunkt
  • Published:
Wiener Medizinische Wochenschrift Aims and scope Submit manuscript

Summary

PSA is without any doubt the most frequently used marker in urology due to its helpful information regarding various aspects of diagnosis, therapy and prognosis in men with prostate cancer. On the other hand, many controversies still exist about the various indications for PSA-determination. The following overview is aimed to analyse the current status of PSA in the management of men undergoing screening, therapy or follow-up of prostate cancer. Anyhow, a detailed knowledge of how to use and interpret PSA and PSA-kinetics is considered to play a crucial role in prostate cancer patients. Current strategies are aimed to start and stop PSA-use earlier.

Zusammenfassung

PSA ist mit Sicherheit der meistgenützte und meistdiskutierte Marker in der Urologie. Der Einsatz von PSA ist in der in der Hoffnung bedingt, Mortalität und Morbidität des Prostatakarzinoms zu senken, welches die häufigste maligne nichtkutane Erkrankung des älteren Mannes in westlichen Industrienationen darstellt. Obwohl es aufgrund des oftmals sehr langen natürlichen Verlaufes bei Prostatakarzinomen sehr schwierig ist, den Nutzen von PSA oder grundsätzlich jeglicher medizinischer Maßnahme nachzuweisen, ist aus der Sicht der Autoren die Häufigkeit der PSA-Bestimmungen sehr wohl bedingt durch die vielfältigen Fragestellungen, wo uns PSA weiterhelfen kann. In Zukunft wird PSA, so nicht ein neuer, potenterer Marker entwickelt und eingeführt wird weiter eine große Rolle spielen. Es wird jedoch auf vielfältige Kenntnisse des behandelnden Arztes ankommen, um karzinomrelevante Informationen jenseits eines einzelnen PSA-Wertes abzuleiten. Der Einsatz von PSA wird eventuell früher beginnen und früher enden (ab 40–75a) und nicht jeder entdeckte Tumor wird tatsächlich auch aktiv therapiert werden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Literatur

  • Yin M, Bastacky S, Chandran U, et al. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol, 179: 892–895, 2008

    Article  PubMed  Google Scholar 

  • Ries LA, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008

  • Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human PSA. Invest Urol, 17: 159–163, 1979

    CAS  PubMed  Google Scholar 

  • Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. PSA as a serum marker for adenocarcinoma of the prostate. N Engl J Med, 317: 909–916, 1987

    Article  CAS  PubMed  Google Scholar 

  • Carroll P, Albertsen K, Greene G, et al. Prostate-specific antigen best practice statement: 2009 update. AUA homepage, 2009

  • Börgermann C, Loertzer H, Luboldt HJ, Hammerer P, Fornara P, Graefen M, Rübben H. PSA – Quo vadis? Urologe A, 98: 1008–1014, 2009

    Google Scholar 

  • Sölétormos G, Semjonow A, Sibley PE, Lamerz R, Petersen PH, Albrecht W, Bialk P, Gion M, Junker F, Schmid HP, Van Poppel H. Biological variation of PSA. Clin Chem, 51: 1342–1351, 2005

    Article  PubMed  CAS  Google Scholar 

  • Loeb S, Roehl KA, Catalona WJ, et al. Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age? BJU Int, 101: 817–821, 2008

    Article  CAS  PubMed  Google Scholar 

  • Cooner WH, Mosley BR, Rutherford CL, et al. PC detection in a clinical urological practice by ultrasonography, digital rectal examination and PSA. J Urol, 143: 1146–1152, 1990

    CAS  PubMed  Google Scholar 

  • Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA, 270: 860–864, 1993

    Article  CAS  PubMed  Google Scholar 

  • Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, Schennach H, Schäfer G, Frauscher F, Boniol M, Severi G, Robertson C, Boyle P, Tyrol Prostate Cancer Screening Group. Tyrol Prostate Cancer Screening Project: early detection, treatment, outcome, incidence and mortality. BJU Int, 101: 809–816, 2008

    Article  CAS  PubMed  Google Scholar 

  • Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med, 360: 1320–1328, 2009

    Article  PubMed  Google Scholar 

  • Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostatecancer screening trial. N Engl J Med, 360: 1310–1319, 2009

    Article  CAS  PubMed  Google Scholar 

  • Thompson IM, Ankerst DP, Etzioni R, Wang T. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol, 4: 1219–1222, 2008

    Article  CAS  Google Scholar 

  • Heidenreich A, Bolla M, Joniau S, et al. Guidelines on Prostate Cancer 2009. European Association of Urology (EAU). http://www.uroweb.org/professional-resources/guidelines/online

  • Loeb S, Gonzalez CM, Roehl KA, et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol, 175: 902–906, 2006

    Article  PubMed  Google Scholar 

  • Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA, 277: 1452–1455, 1997

    Article  CAS  PubMed  Google Scholar 

  • Partin AW, Kattan MW, Subong ENP, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA, 277: 1445–1451, 1997

    Article  CAS  PubMed  Google Scholar 

  • Kattan MW, Vickers AJ, Yu C. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized PC. Cancer, 115: 1005–1010, 2009

    Article  PubMed  Google Scholar 

  • Karakiewicz PI, Hutterer GC. Predicitve models and prostate cancer. Nat Clin Pract Urol, 5: 82–92, 2008

    Article  PubMed  Google Scholar 

  • Rietbergen JB, Hoedemaeker RF, Kruger AE, et al. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol, 161: 1192–1198, 1999

    Article  CAS  PubMed  Google Scholar 

  • Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology, 58: 843–848, 2001

    Article  CAS  PubMed  Google Scholar 

  • Freedland SJ, Mangold LA, Walsh PC, et al. The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol, 174: 1276–1281, 2005

    Article  CAS  PubMed  Google Scholar 

  • Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol, 24: 3984–3990, 2006

    Article  PubMed  Google Scholar 

  • Stewart AJ, Scher HI, Chen MH, et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol, 23: 6556–6560, 2005

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anton Ponholzer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ponholzer, A., Stoiber, F., Loidl, W. et al. Aktueller Einsatz von PSA. Wien Med Wochenschr 159, 515–520 (2009). https://doi.org/10.1007/s10354-009-0718-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10354-009-0718-0

Keywords

Schlüsselwörter

Navigation